March 28 (Reuters) - Gene therapy maker bluebird bio BLUE.O said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Bluebird bio, which has been facing a cash crunch, first raised going-concern doubts three years ago. It laid off a quarter of its workforce last year to focus on launching three gene therapies, including Lyfgenia for sickle cell disease, which has had slow uptake.
Ayrmid, the parent company of cell therapy developer Gamida Cell, offered to acquire bluebird for $4.50 per share upfront, totalling about $43.8 million, according to Reuters calculations using data compiled by LSEG.
The privately held UK company also offered an additional $6.84 per share, representing about $66.6 million, contingent upon bluebird achieving certain sales milestones.
In February, bluebird bio said it had agreed to be taken private by Carlyle Group CG.O and SK Capital Partners, for $3 per share upfront along with the same $6.84 per share, contingent upon it achieving certain sales milestones.
Bluebird said its board is reviewing the Ayrmid proposal in consultation with its legal and financial advisors, and the board has not changed its recommendation in support of the Carlyle and SK Capital Partners deal.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。